NeurogesX Initiate Phase I of NGX-1998 Capsaicin Liquid Formulation « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
July 2008

M T W T F S S

« Jun Aug »

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30 31

NeurogesX Initiate Phase I of NGX-1998 Capsaicin Liquid Formulation

Posted on July 14, 2008 by crimsoncanary

NeurogesX has initiated a Phase 1 clinical trial of NGX-1998, a high-concentration, capsaicin-based liquid formulation designed to deliver a localized therapeutic dose directly to the pain site.

Filed under: gpcr | Tagged: agonist, Capsaicin, NeurogesX, NGX-1998, NGX1998, TRPV1, Vanilloid

« GlaxoSmithKline license Actelions orexin receptor antagonist almorexant Theravance annouces positive Phase II results of MABA GSK961081 in COPD »

Leave a Reply